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Thoracic Operations for Pulmonary Nodules Are Frequently
Not Futile in Patients with Benign Disease
Eric L. Grogan, MD, MPH,*†‡ Jodi J. Weinstein, MD,* Stephen A. Deppen, MA, MS,*
Joe B. Putnam, Jr., MD,*† Jonathan C. Nesbitt, MD,*† Eric S. Lambright, MD,*†
Ronald C. Walker, MD,§ Robert S. Dittus, MD, MPH,‡ and Pierre P. Massion, MD¶#
Introduction: Pulmonary nodules often require operative resection
to obtain a diagnosis. However, 10 to 30% of operations result in a
benign diagnosis. Our purpose was to determine whether negative
thoracic operations are futile by describing the pathological diagno-
ses; determining new diagnoses and treatment changes initiated
based on operative findings; and assessing morbidity, mortality, and
cost of the procedure.
Methods: At our academic medical center, 278 thoracic operations
were performed for known or suspected cancer between January 1,
2005, and April 1, 2009. We collected and summarized data per-
taining to preoperative patient and nodule characteristics, pathologic
diagnosis, postoperative treatment changes resulting from surgical
resection, perioperative morbidity and mortality, and hospital
charges for patients with benign pathology.
Results: Twenty-three percent (65/278) of patients who underwent
surgical resection for a suspicious nodule had benign pathology. We
report granulomatous disease in 57%, benign tumors in 15%, fibro-
sis in 12%, and autoimmune and vascular diseases in 9%. Definitive
diagnosis or treatment changes occurred in 85% of cases. Surgical
intervention led to a new diagnosis in 69%, treatment course
changes in 68% of benign cases, medication changes in 38%, new
consultation in 31%, definitive treatment in 9%, and underlying
disease management in 34%. There was no intraoperative, in-
hospital, or 30-day mortality. Postoperative in-hospital events oc-
curred in seven patients. The mean total cost was $25,515 with a
mean cost per day of $7618.
Conclusions: Patients with a benign diagnosis after surgical resec-
tion for a pulmonary nodule received a new diagnosis or had a
treatment course change in 85% of the cases.
Key Words: Pulmonary nodule, Benign nodule, Lung cancer, Bi-
opsy (lung), Thoracic surgery, Clinical decision making.
(J Thorac Oncol. 2011;6: 1720–1725)
Lung cancer remains the most common cause of cancer-related death worldwide.1 Computed tomography (CT)
has recently been shown to reduce lung cancer mortality,2 but
radiographic screening reveals pulmonary nodules in 8 to
51% of patients, with malignancy in 1 to 12% of patients.3,4
In clinical practice, 31 to 82% of nodules are malignant; thus,
most patients require additional diagnostic tests.4 Despite
advances in clinical assessment and imaging, tissue diagnosis
requiring thoracoscopy or thoracotomy is often necessary and
remains the gold standard.5 At the time of surgical resection,
if malignancy is revealed on frozen sections, then definitive
anatomic resection with staging is usually performed. No
additional surgery is usually required for those with benign
disease. Therefore, in cases demonstrating a high preopera-
tive probability of malignancy, surgical resection provides
opportunities for both diagnosis and definitive therapeutic
intervention.
Recent reports have referred to invasive procedures that
yield a benign diagnosis as “of limited or no clinical signif-
icance,” “negative resection,” “futile thoracotomy,” “non-
therapeutic resection,” “overuse of an invasive procedure,” or
“unnecessary surgery.”5–8 Rates of benign disease have
ranged in recent reports from 1 to 30% of surgical resection
cases for suspected lung cancer, depending on patient popu-
lation and preoperative evaluation protocol.7,9 Thus, the in-
vasive thoracic procedure has been perceived to cause unnec-
essary cost, societal burden, and morbidity and mortality risk
to the patient, with no therapeutic benefit.7,8,10–12 Most de-
scriptive studies of patients who have undergone surgical
resection of suspicious pulmonary nodules limit their analysis
of benign cases to the diagnoses and costs of preoperative
evaluation,7,10,12–14 with no evaluation of whether this benign
diagnosis affects subsequent patient management. We there-
fore hypothesized that surgical resection of these benign
nodules presenting as suspicious nodules improves patient
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management. To determine what influences, if any, benign
nodule resection has on patient management, we aimed to (1)
describe the pathologic diagnosis of surgically resected be-
nign pulmonary nodules, (2) determine what new diagnoses
and medication and/or treatment changes resulted from the
operative findings, and (3) assess the morbidity, mortality,
and cost of the procedure.
MATERIALS AND METHODS
Population
We reviewed data from 278 consecutive thoracic oper-
ations performed by the Vanderbilt Department of Thoracic
Surgery for known or suspected lung cancer between January
1, 2005, and April 1, 2009. Figure 1 details the flow of
analysis of cases, from the 2288 patient database to the
population of interest. Pulmonary nodule was broadly defined
to include radiological abnormalities of different shapes.
Patients with multiple pulmonary opacities or nodular infil-
trates were excluded if preoperative suspicion for lung cancer
could not be established. Sixty-five cases were diagnosed
with benign pathology and were included in this study. The
Vanderbilt University Institutional Review Board approved
this retrospective descriptive study and waived the need to
obtain individual patient consent (IRB #081298).
Data Sources
Patients were identified using Vanderbilt’s Thoracic
Surgery Database, which contains prospective, surgeon-
recorded demographic and perioperative data for all patients
who had received a thoracic surgical operation at Vanderbilt
since January 1, 2005. At the time of this study, the database
included 2288 patients. For all patients, complete preopera-
tive, operative, and postoperative notes—as well as imaging,
pathology, and microbiology reports—are prospectively doc-
umented by treating physicians in the electronic medical
record. Hospital, clinic, and professional fees before, during,
and after operation are prospectively included for all patients
in Vanderbilt’s administrative database.
Data Collection, Classification, and Analysis
Specific variables for patient demographics, preopera-
tive nodule characteristics, operative findings, postoperative
diagnoses, medication and treatment course changes, and
30-day survival were extracted from the Thoracic Surgery
Database and electronic medical record. Preoperative im-
aging characteristics of benign nodules (size, location,
morphology, and interval growth) were recorded verbatim
from the radiologist’s CT review. Images were reviewed
by one of the author (R.W.) if there was no written
description of edge or consistency. The nodule was avid if
the fluorodeoxyglucose positron emission tomography
(FDG-PET) report, as dictated by the radiologist, noted a
standardized uptake value exceeding 2.5. If no value was
reported, FDG-PET was classified as avid if the radiologist
reported a suspicion of malignancy and used the terms
“cancerous,” “likely,” “possible,” or “probable.”
Pathologic diagnosis was extracted from the pathology
report and categorized between granulomatous disease, be-
nign tumors, fibrosis, autoimmune and vascular diseases, and
others. The category “granulomatous disease” was subdi-
vided into active-infectious and healed-or-nonspecific
groups. Infectious etiology was indicated by the pathologist’s
report of morphology on specimen stain or microbiologist’s
growth report. The diagnosis was defined as active-infectious
histoplasmosis if histopathology reported yeast forms com-
patible with Histoplasma capsulatum or microbiology re-
ported growth of H. capsulatum in fungal culture.15 If pathol-
ogy reported infectious granulomatous disease with unknown
organisms and microbiology was nonrevealing, “infectious
granulomata, organism unknown” was recorded. Granuloma-
tous disease with no identifiable etiology was recorded as
“healed or nonspecific.”
For each benign case, medical records were reviewed to
collect data on new diagnosis, specialty service consultations,
FIGURE 1. Patient selection criteria. Flow diagram of pa-
tient selection from all Vanderbilt Thoracic Surgery cases
considered (n  2288) to the subset of benign cases ana-
lyzed (n  65) with inclusion and exclusion criteria noted.
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reliance for underlying disease management, and changes in
treatment due to operative findings or postoperative diagno-
sis. New diagnosis was classified as positive if pathology,
microbiology, or provider gave a new diagnosis at postoper-
ative follow-up with documentation in the medical record.
Medication change was defined as the postoperative initiation
of a new therapeutic medication or discontinuation of a
medication no longer indicated, recommended by the surgeon
or surgeon’s consultant, and documented by the thoracic
surgeon in the postoperative note. The management of the
primary diagnosis being contingent on nodule pathology was
determined from the perioperative referral and thoracic sur-
gery notes. These influences of operation on treatment course
were considered independently and not mutually exclusive.
Postoperative hospital course event variables were cap-
tured prospectively from Vanderbilt’s Thoracic Surgery Da-
tabase and extracted directly for all 65 patients with benign
nodules. Events included in-hospital mortality, wound infec-
tion, ventilation requirement exceeding 48 hours, reintuba-
tion, air leak exceeding 4 days, pneumothorax, postoperative
bleed, atrial fibrillation, change in status, and hospital dis-
charge with chest tube. Length of stay data were extracted
from Vanderbilt’s administrative database and 30-day mor-
tality from the medical record. Cost of care for each inpa-
tient’s operative stay was based on hospital fees retrieved by
administrative chart abstraction and estimated using the med-
ical center’s internal activity-based cost accounting system
(TSI/Eclipsys) for base year 2009. We applied our institution-
specific inflation factor to total inpatient costs based on
discharge date of the patient. In those cases where costs were
not available, a cost-to-charge ratio of 0.6 was applied to total
inpatient charges before adjusting costs to the base year of
2009. Descriptive statistics were performed on deidentified
data using STATA (version 9, College Station, TX).
RESULTS
Surgical resection was performed in 278 patients with
suspicious lesions. Pathologic diagnosis was benign in 65
cases (23%), and the mean age was 52  13.6 years (Table
1). Of this group, 64% were current or former smokers
(average 38.5 pack-years), and preoperative history of ex-
trathoracic cancer was present in 17 patients. Preoperative CT
imaging was performed on all 65 patients and mean nodule
size was 20.8  12.6 mm (range, 4–63 mm) (Table 2). CT
imaging data regarding nodule size distribution, edge char-
acteristics, interval growth, and location are reported in Table
2. Of the benign nodules, 42 were imaged using FDG-PET,
and 26 of these were FDG-PET avid (62%). Preoperative fine
needle aspiration was performed in 15 cases. Patients under-
went sublobar resection in 54 cases (83%), lobectomy in 9
(14%), and thoracotomy with nodule biopsy or excision in 2
(3%). The thoracic operation was limited to video-assisted
thoracic surgery in 43 cases (66%). Pathologic evaluation
revealed granulomatous disease in 37 of the 65 benign nod-
ules (Table 3); these were active infectious granulomata in
27, 15 of which corresponded to active histoplasmosis. Be-
nign tumors were identified in 10 cases (15%), fibrosis in 8
(12%), and autoimmune or vascular diseases in 6 (9%).
Operative findings led to a new diagnosis in 45 of the
65 patients in the benign group (69%) and changed the
treatment course for 44 patients (68%) in one or more ways
(Table 4). New diagnosis led to a medication change for 24
patients and new consultations in 20 benign cases. Develop-
ment of a treatment plan for the management of an underlying
disease awaited nodule diagnosis in 22 cases, including 17
patients with extrathoracic cancer and 1 with a prior lung
cancer resection for whom recurrence was subsequently no
longer suspected. Resection was therapeutic for one patient
with an enlarging hamartoma encroaching on the pulmonary
artery, two patients with an obstructed airway causing recur-
rent infection, and three patients with premalignancy. Prema-
lignancy was specified in the pathologist’s report for (1)
inflammatory myofibroblastic tumor, (2) atypical lym-
phoproliferation, and (3) neuroendocrine cell hyperplasia.
In 10 cases (15%), neither a new diagnosis nor a change in
management resulted from operative findings. These 10
cases included 5 granulomata not otherwise specified, 2
fibrotic nodules, reactive lymph node, rheumatoid nodule,
and hamartoma. Thus, nodule resection resulted in a new
TABLE 1. Characteristics of Patients with Benign Nodules
(n  65)
Age (yr) 52 (13.6)
Gender
Male 32 (49%)
Female 33 (51%)
BMI 29 (5.7)
Smoking history
Never smoked 23 (35%)
Current smoker 7 (11%)
Former smoker 35 (54%)
Pack-yearsa 38.5 (26.3)
Preoperative hemoptysis 4 (6%)
Preoperative cancer diagnosis (extrathoracic) 17 (26%)
Zubrod Performance Scoreb 0.48 (0.62)
Preoperative ASA
Class I, healthy 9 (14%)
Class II, mild systemic disease 24 (37%)
Class III, severe systemic disease, function-limiting 30 (46%)
Class IV, severe systemic disease, life-threatening 2 (3%)
FEV1c
Preoperative predicted (%) 82 (23)
Preoperative actual (L/sec) 2.7 (0.93)
Thoracic operation
Sublobar resection (wedge or segmentectomy) 54 (83%)
Lobectomy 9 (14%)
Otherd 2 (3%)
VATSe 43 (66%)
Values are given as N (%) or mean (SD).
a Mean over all ever-smokers.
b SD with 2 missing.
c SD with 15 missing.
d One thoracotomy with multiple core needle biopsies and one thoracotomy with
excision of a nodal mass within the left upper lobe.
e VATS with 42 wedge resections and 1 lobectomy.
ASA, American Society of Anesthesiologists; BMI, body mass index; FEV1, forced
expiratory volume in 1 sec; VATS, video-assisted thoracoscopic surgery.
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diagnosis, medication change, new consultation, underlying
disease management, or definitive therapy in 55 of 65 total
cases (85%).
The mean hospital stay for patients in the benign group
was 3.7 days (excluding one outlier of 44 days). There was no
intraoperative, in-hospital, or 30-day death (Table 5). Post-
operative in-hospital events occurred in seven patients (11%)
and included pleural air leaks that exceeded 4 days in two
cases (3%), reintubation in one, postoperative bleeding in
one, and atrial fibrillation in one patient. There were no cases
of wound infection, requirement of ventilation for more than
48 hours, or change in patient status. The mean total cost was
$25,518 (median  $19,894), with a cost per day of $6891.
DISCUSSION
Futile thoracotomies pose unnecessary risk and burden
on patients and society. However, we demonstrate in this
investigation that only 10 of 65 thoracic operations (15%) for
pulmonary nodules yielding a benign diagnosis are futile.
Surgical wedge resection or lobectomy led to a new diagnosis
in 69% of benign cases and changed treatment in 68% of
cases. In one-third of cases (34%), findings directed manage-
ment of an underlying disease, including concurrent extratho-
racic cancer in 26% of our benign group and transplant
management in 6% (four cases). In six cases (9%), resection
resulted in definitive treatment. In 55 of 65 cases (85%),
patients with benign diagnosis after surgical resection directly
benefited from the surgical intervention.
A prevalence of granulomatous disease within our pa-
tient population likely accounts for the relatively high benign
rate in our study. The proportion of patients with granuloma-
tous disease in this series (57%) is near the higher end of the
previously reported (40–65%) ranges.5,7,16 Gould et al.,17 in
a meta-analysis of 10 PET imaging studies published between
1993 and 1998, found the most common benign diagnosis to
be granulomatous disease (40%), with active granulomatous
infection reported in only 15% of benign cases. In our study,
active infection accounted for 42%; this increased prevalence
deriving from a high percentage of H. capsulatum-containing
granulomata (23%) within our cohort. While Gould’s meta-
analysis combined studies from a variety of geographical
TABLE 2. Benign Pulmonary Nodule Characteristics (n  65)
Preoperative CT performed 65 (100%)
Mean nodulea size on CT (mm) 20.8 (12.6)
Size distribution
10 mm 18 (28%)
11–20 mm 20 (31%)
20–30 mm 10 (15%)
30 mm 17 (26%)
CT edge
Smooth 27 (42%)
Lobulated 14 (22%)
Spiculated 22 (34%)
Not described 2
CT consistency
Cavitary 7 (11%)
Semisolid 3 (5%)
Solid 53 (82%)
Ground glass 1 (1.5%)
Not described 1
Nodule growth reported by CT 22 (34%)
CT location
Left upper lobe 16 (25%)
Left lower lobe 6 (9%)
Right upper lobe 19 (29%)
Right middle lobe 8 (12%)
Right lower lobe 6 (9%)
Not reported 10 (15%)
Preoperative FDG-PET performed 42 (65%)
FDG-PET avidb 26/42 (62%)
Preoperative FNA biopsy performed 15 (23%)
Values are given as N (%) or mean (SD).
a The majority of lesions were 3 cm; there were 17 “masses” (3 cm). The term
nodule is used throughout the article for consistency acknowledging that a small
percentage were actually masses.
b FDG-PET avid defined as SUV 2.5 or mild, moderate, or intense uptake, or
radiology report indicated suspicion of cancer.
CT, computed tomography; FDG-PET, fluorodeoxyglucose-positron emission to-
mography; FNA, fine needle aspiration; SUV, standardized uptake value.
TABLE 3. Pathology of Benign Nodules
N (%)
(n  65)
FDG-PET
Avida
(n  26)
FDG-PET
Nonavid
(n  16)
Granulomatous disease 37 (57%) 15 9
Active infectious 27 (42%)
Histoplasmosis 15 (23%) 5 3
Atypical mycobacteria 2 (3%) — 1
Blastomycosis 2 (3%) 1 —
Cryptococcus 2 (3%) 1 —
Mycobacterium tuberculosis 1 (1.5%) 1 —
Aspergillus 1 (1.5%) — —
Actinomyces 1 (1.5%) 1 —
Nocardia 1 (1.5%) — 1
Mucor 1 (1.5%) — —
Organism unknown 1 (1.5%) 5 4
Healed or nonspecific 10 (15%) — —
Benign tumors 10 (15%) 2 5
Hamartoma 6 (9%) 1 3
Assorted benign tumorsb 4 (6%) 1c 2d
Fibrosis 8 (12%) 3 2
Autoimmune and vasculitides 6 (9%) 3 —
Wegener granulomatosis 3 (5%) 2 —
Pneumonitis 1 (1.5%) 1 —
Rheumatoid 1 (1.5%) — —
Churg-Strauss vasculitis 1 (1.5%) — —
Othere 4 (6%) 3 —
a FDG-PET avid defined as SUV 2.5 or mild, moderate, or intense uptake, or
radiology report indicated suspicion of cancer.
b Assorted benign tumors: lipoma, premalignancy was specified in the pathologist’s
report for (1) inflammatory myofibroblastic, (2) atypical lymphoproliferative, and (3)
neuroendocrine cell hyperplasia.
c Inflammatory myofibroblastic.
d Atypical lymphoproliferative and lipoma.
e Other: bronchiolitis obliterans organizing pneumonia, broncholith with postob-
structive pneumonia, reactive lymph nodes, infarct with organizing thrombus.
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regions, our patient population was drawn from a tertiary
academic medical center located in Nashville, TN. H. capsu-
latum is endemic within our region, and 57 to 100% of the
population has reported exposure.18–20
We report several cases of infectious nodules that, in
hindsight, may be appropriately managed by surgical resec-
tion, although we do not assume this to be the optimal
approach. Nonetheless, when antibiotic therapy is given em-
pirically for indeterminate nodules, medical management
alone has shown to provide limited benefit.5,21 Premalignancy
is another example of benign nodule pathology potentially
managed with resection. Further analysis of various com-
bined medical and surgical management approaches for in-
fectious and premalignant nodules is needed to propose
guidelines for best management of indeterminate pulmonary
nodules.
Our morbidity, mortality, and cost results are particu-
larly relevant for the development of evidence-based com-
parative effectiveness guidelines in the management of pa-
tients with suspicious pulmonary nodules found both in
clinical practice and in CT screening programs. Prior models
have calculated life expectancy of patients undergoing resec-
tion of a benign nodule resection as their normal life expec-
tancy minus the morbidity of surgery.22,23 The more recent
model of Gould et al.24 adjusted life expectancy for quality of
life using age- and sex-specific utilities and estimated health
care costs for patients with benign nodules, including age-
specific, annual health care expenditures. However, the as-
sumption that outcomes of benign diagnoses correspond to
the normal population has been challenged recently as over-
simplification and underestimation of morbidity, mortality,
and costs associated with benign diagnoses.14 Barnett et al.
suggested that evaluation alone of infectious nodules incurs
cost and morbidity comparable to that of malignancy. We
have extended their work by specifically identifying the costs
and morbidity associated with ruling out malignancy in a
high-risk population and adding the value of the clinical
information resulting from the pathology or microbiology
reports. Because our data do not include the treatment cost of
the benign diagnoses, the results represent a conservative
estimate. The expenses of both ruling out malignancy and
treating benign diseases must be factored into future manage-
TABLE 4. Influences of Operation and Postoperative
Diagnosis on Patient Treatment Courses (n  65)
New diagnosisa 45 (69%)
Treatment course changed by results 44 (68%)
New consultations for new diagnosis 20 (31%)
Total number of new consultations 25
Consult service
Infectious disease 15
Pulmonology 4
Rheumatology 3
Hematology 1
Other (nephrology and transplant) 2
Change in medication regimenb 24 (37%)
Antifungal initiated 11 (17%)
Immunosuppressant initiated 4 (6%)
Chemotherapy initiated 3 (5%)
Immunosuppressant held or discontinued 2 (3%)
Antibiotic initiated 2 (3%)
Otherc 2 (3%)
Management of underlying disease contingent on diagnosis
or procedure
22 (34%)
Treatment of extrathoracic cancerd 17 (26%)
Transplant management 4 (6%)
Rule out metastatic lung cancer 1 (1.5%)
Resection was therapeutice 6 (9%)
Total patients with new diagnosis or treatment course
change
55 (85%)
Total patients with neither new diagnosis nor treatment
course changef
10 (15%)
Values are given as N (%).
a Definitive diagnosis on pathology or microbiology or new diagnosis given by
provider at follow-up.
b Defined by postoperative initiation of a new therapeutic medication or discontin-
uation of medication no longer indicated.
c Other changes included initiation of somatostatin-analog and antituberculosis
therapies.
d Extrathoracic cancers were most commonly breast, squamous cell of head and
neck, and lymphomatous.
e Resection was therapeutic for one patient with enlarging hamartoma encroaching
on pulmonary artery, two patients with an obstructive nidus for recurrent infection, and
three with premalignancy.
f Cases without new diagnosis or treatment course change included five granulo-
mata not otherwise specified, two fibrotic nodules, reactive lymph node, rheumatoid
nodule, and hamartoma.
TABLE 5. Hospital Events and Costs (n  65)
Hospital Course
Intraoperative deaths 0
In-hospital mortality 0
30-d mortality 0
Patients with a postoperative event 7 (11%)
Lobectomy patients with long-term respiratory
difficultiesa
3
Events
Discharge with chest tube 4 (6%)
Air leak 4 d 2 (3%)
Reintubation 1 (1%)
Postoperative bleeding 1 (1%)
Atrial fibrillation 1 (1%)
Pneumothorax 0
Ventilation 48 h 0
Wound infection 0
Change in status 0
Length of stay (d)b 3.7 (3.1)
Costsb,c
Mean total cost (median) $25,518 ($19,894)
Cost per day $6891
Values are given as N (%) or mean (SD).
a Subset analysis of the nine lobectomy cases for postdischarge sequelae revealed
two patients with mild exercise limitations and one patient who was discharged on
temporary home oxygen.
b One outlier of 44 d was excluded from length of stay, mean total cost, and cost
per day. When included, the mean length of stay was 4.3, mean total cost $28,006,
median total cost $20,344, and cost per day $6478.
c Cost is determined from charge data, by factoring in cost-to-charge conversion
(0.6) and an institutional-specific inflation factor to make costs comparable in the base
year 2009.
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ment models for patients with indeterminate nodules in en-
demic areas with histoplasmosis. This data will also be
applicable for determining the cost-effectiveness of CT
screening programs in these geographic regions.
Several limitations of our descriptive study must be
noted. The study population was specifically defined to in-
clude only those thoracotomies deemed “futile” for their
benign diagnosis and those benign nodules suspicious for
malignancy. “Futile thoracotomies” referring to incomplete
resection of high-stage non-small cell lung cancer25 were not
included. Similarly, indications for thoracic intervention
other than ruling out lung cancer, such as diagnostic wedge
biopsies for diffuse infiltrates or multiple nodules, were
excluded. Finally, patients with benign diagnoses may have
received more aggressive management than diagnostically
similar nonoperative candidates because the former received
multispecialty care in a tertiary center. Therefore, our find-
ings may not be generalizable to a broader population and
should be applied within similar context. Our outcome results
are also limited and potentially biased by retrospective data
capture in only those patients who received an operation, so
analysis did not include those followed with serial imaging.
However, even if overclassification occurred, this could not
explain the magnitude of our results.
Additional research is needed to elucidate reliable non-
invasive alternatives to diagnostic operative resection that can
identify benign diagnoses preoperatively. Increased sensitiv-
ity for common benign diagnoses may help decision making
regarding preoperative probability of malignancy and guide
appropriate treatment of benign nodules. In particular, ad-
vances in preoperative diagnostic discrimination between
infectious granulomata and autoimmune nodules may signif-
icantly reduce the number of cases currently indicated for
diagnostic operation by influencing physicians’ willingness to
try antifungal or immunosuppressive medications when the
risk involved in this therapy approaches that of surgery. A
prospective study including patients managed both medically
and surgically is needed to determine the best treatment
options for these patients.
We conclude that patients who receive a benign diag-
nosis after surgical evaluation for a pulmonary nodule may
benefit from this intervention with minimal surgical morbid-
ity and mortality. In addition, obtaining this new information
from surgical resection has considerable costs, and further
studies are needed to determine the most cost-effective strat-
egies for management of such patients.
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